Academic Journal
BAY 94-9027 prophylaxis is efficacious and well tolerated for up to >5 years with extended dosing intervals: PROTECT VIII extension interim results
| العنوان: | BAY 94-9027 prophylaxis is efficacious and well tolerated for up to >5 years with extended dosing intervals: PROTECT VIII extension interim results |
|---|---|
| المؤلفون: | Lalezari, Shadan, Reding, Mark T., Pabinger, Ingrid, Holme, Pål Andre, Negrier, Claude, Chalasani, Pavani, Shin, Ho-Jin, Wang, Maria, Tseneklidou-Stoeter, Despina, Enriquez, Monika Maas |
| المصدر: | 1351-8216. |
| سنة النشر: | 2020 |
| المجموعة: | Universitet i Oslo: Digitale utgivelser ved UiO (DUO) |
| الوصف: | Introduction BAY 94‐9027 is an extended‒half‐life, site‐specifically PEGylated, B‐domain‒deleted recombinant factor VIII (FVIII). The PROTECT VIII main study demonstrated efficacy of bleed control using extended‐interval prophylaxis with BAY 94‐9027 for 36 weeks. Aim To report long‐term efficacy and safety of prophylaxis with BAY 94‐9027 in a descriptive analysis of the ongoing PROTECT VIII extension with a total treatment time of up to >5 years. Methods Previously treated males aged 12‐65 years with severe haemophilia A who completed the PROTECT VIII main study were eligible for the open‐label extension. Patients received on‐demand treatment or prophylaxis (30‒40 IU/kg twice weekly, 45‒60 IU/kg every 5 days, or 60 IU/kg every 7 days) and could switch regimens as needed. Results Patients (N = 121; on demand, n = 14; prophylaxis, n = 107) accumulated a median (range) of 3.9 years (297‒1965 days) and 223 (23‒563) total exposure days by 31 January 2018. During the extension, median (quartile [Q]1; Q3) annualized bleeding rates (ABRs) for total bleeds were 1.6 (0.3; 4.6) for patients receiving prophylaxis and 34.1 (20.3; 36.6) for patients receiving on‐demand treatment. ABRs for twice‐weekly (n = 23), every‐5‐days (n = 33), every‐7‐days (n = 23) and variable frequency (n = 28) treatments were 1.7, 1.2, 0.7 and 3.1, respectively. Of prophylaxis patients, 20.6% were bleed‐free throughout the extension (median time, 3.2 years), and 51.0% were bleed‐free during the last 6 months. No patients developed FVIII inhibitors. Conclusions BAY 94‐9027 prophylaxis was efficacious and well tolerated with dosing intervals up to every 7 days for a median (range) of 3.9 years (0.8‐5.4 years). |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| Relation: | http://urn.nb.no/URN:NBN:no-79011; Lalezari, Shadan Reding, Mark T. Pabinger, Ingrid Holme, Pål Andre Negrier, Claude Chalasani, Pavani Shin, Ho-Jin Wang, Maria Tseneklidou-Stoeter, Despina Enriquez, Monika Maas . BAY 94-9027 prophylaxis is efficacious and well tolerated for up to >5 years with extended dosing intervals: PROTECT VIII extension interim results. Haemophilia. 2019, 25(6), 1011-1019; http://hdl.handle.net/10852/75885; 1770623; info:ofi/fmt:kev:mtx:ctx&ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Haemophilia&rft.volume=25&rft.spage=1011&rft.date=2019; Haemophilia; 25; 1011; 1019; https://doi.org/10.1111/hae.13853; URN:NBN:no-79011; Fulltext https://www.duo.uio.no/bitstream/handle/10852/75885/2/BAY%2B94-9027%2Bprophylaxis%2Bis%2Befficacious%2Band%2Bwell%2Btolerated%2Bfor%2Bup%2Bto%2B5%2Byears%2Bwith%2Bextended%2Bdosing%2Bintervals%2BPROTECT%2BVIII%2Bextension%2Binterim%2Bresults.pdf |
| DOI: | 10.1111/hae.13853 |
| الاتاحة: | http://hdl.handle.net/10852/75885 http://urn.nb.no/URN:NBN:no-79011 https://doi.org/10.1111/hae.13853 |
| Rights: | Attribution-NonCommercial-NoDerivatives 4.0 International ; https://creativecommons.org/licenses/by-nc-nd/4.0/ |
| رقم الانضمام: | edsbas.EEEAD13B |
| قاعدة البيانات: | BASE |
| DOI: | 10.1111/hae.13853 |
|---|